Serina Therapeutics, based in Alameda, California, is a clinical-stage biotechnology company developing drug candidates for neurological diseases, focusing on SER-252 for Parkinson's Disease. The company went public on November 29, 2018, and employs four people.
Gregory Bailey bought 3,866 shares of SER on 17 December at $4.59 per share, worth a total of $18K. They now own 67,243 SER shares, or a 6% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
